- Biopharmaceutical company Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced that it has licensed the intellectual property rights related to the development of a medical device that has the potential to enable public health professionals to immediately diagnose COVID-19 infection with a breath sample.
Biopharmaceutical company Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced that it has licensed the intellectual property rights related to the development of a medical device that has the potential to enable public health professionals to immediately diagnose COVID-19 infection with a breath sample and track through a mobile device from the George Washington University (GW).
Dr. Mona E. Zaghloul, a professor of Electrical and Computer Engineering at GW School of Engineering and Applied Science, and former doctoral student Yangyang Zhao, developed the design of the device. The technology is based on prior work of other former students in collaboration with the National Institute of Standards and Technology to detect and distinguish different species of gas.
This device is based on nanotechnology Nanoholes using Plasmonics principles. And the surface of the device is covered in a thin sheet of gold that is able to bind with other molecules like those of a gas.
When the binding occurs, the wavelength of light bouncing off the surface changes thus creating a different color of light. And different gases would cause different shifts in light.
The results can be available quickly and AI programs can then classify the molecules that are bound to the surface of the device. And the results — including the different classes of the molecules — can then be sent to the cloud by a mobile device, allowing the ability to track the data.
Dr. Jeanne Jordan, PhD, a professor in Epidemiology at the GW Milken Institute School of Public Health, was instrumental in recognizing the potential diagnostic capabilities of the technology. And as the COVID-19 pandemic spreads, she suggested alterations to the device.
The researchers believe that the modified apparatus — which is as small as a strand of hair — can be coated with a solution designed to bind specifically to the SARS-CoV-2 virus that causes COVID-19. And this design would allow the virus to bind to the surface thus allowing for the detection of an optical change that could immediately be sensed by phone cameras when an infected person’s specimen is applied.
Dr. Zaghloul and Dr. Jordan’s research was funded by a COVID-19 Technology Maturation Grant from GW’s Technology Commercialization Office in order to accelerate the development of this medical device. And the device would allow communities to build trackable real-time databases of infection. People can upload information directly to the cloud.
KEY QUOTES:
“These are devices that a public health professional could go out with into the field to administer point-of-care testing, either at a walk-up center or directly in the community. They’re extremely rapid—the turnaround time to having test results is within minutes, and you do the testing right there instead of having to send your sample to a large commercial laboratory with a massive backlog. That would allow these professionals to say immediately if someone needs to be quarantined, and to get the names of their contacts so they can start contact tracing.”
— Dr. Jordan
“The immediate diagnosis and ongoing tracking of COVID-19 is a critical initiative towards mitigating the ongoing spread of COVID-19. This device which is under development would allow users to conduct widespread testing and provide instantaneous results through the administration of a breath sample and tracking through a mobile device. Securing the rights to this paradigm shifting technology in the fight against the global COVID-19 pandemic is a significant opportunity for Hoth and its shareholders. We look forward to working with the team at GW to accelerate the development of this breakthrough technology.”
— Robb Knie, Chief Executive Officer of Hoth
